Background Several guidelines exist on the appropriate use of serum tumour markers in the management of patients with cancer. This study audited tumour marker requesting against these guidelines in a busy teaching hospital over a 12month period.
Introduction
The use of serum tumour markers in the management of malignant disease has become established practice, 1^3 and their measurement forms a mainstay of the modern pathology laboratory. However, the speci¢c role that tumour markers may ful¢l is a subject of deliberation, 4^7 and whether marker testing could be utilized outside the currently held guidelines 2, 3, 8 continues to be debated. 9^11 Whilst many biological factors are known to be produced as a result of malignant growth, 5,12^15 a select series of tumour markers are readily associated with cancer development and thus frequently requested by clinicians. 2^4,10,16 In particular, the measurement of carcinoembryonic antigen (CEA) in cases of colorectal adenocarcinoma 2, 3, 10, 17, 18 and cancer antigen (CA) 125 during the treatment of ovarian disease 2, 9, 11, 16, 17, 19 are routinely requested. In addition, the testing of carbohydrate antigen (CA) 19-9 1 and cancer antigen (CA) 15-3 for pancreatic 12, 17 and breast 3, 17, 19 cancer, respectively, are commonly performed, as is the measurement of prostate-speci¢c antigen (PSA) in prostate cancer. 4, 5, 7, 15, 20 The management of germ-cell malignancies 1,3 also often entails the dual measurement of a-fetoprotein (AFP) and human chorionic gonadotrophin (hCG). 1^3,18 Although increased levels of serum tumour markers are often associated with the presence of cancer, 2^5,7,16,17,20 marker concentrations may also rise in a number of benign conditions 1^3,9,18,21 and metabolic or hormonal changes. 2, 9, 19 Conversely, a malignancy may not generate elevated tumour marker concentrations until late in its development, 6, 9, 11, 15, 16 if at all, and none of the main tumour markers are wholly speci¢c to a single cancer type. 2, 3, 17, 18 To this end, most guidelines recommended to clinicians 2, 3, 8 state that tumour markers such as CEA, CA15-3, CA125 and CA19-9 should only be used once a conclusive diagnosis of malignant disease has been achieved, and that marker assays are applied speci¢cally to monitor response to treatment, 2,3,16,17 screen for potential reoccurrence 2 and as a prognostic indicator. 1, 2, 16, 22 Original Article Notwithstanding these recommendations, extending the use of tumour marker testing to diagnose or case ¢nd malignant disease has generated considerable interest 4^7,9^12,15,23 with the instigation of studies to assess the merits of inclusion in the diagnostic process. 23 Indeed, in some areas of cancer diagnosis the use of tumour markers is already advocated by some, 7, 20 despite evidence relating to the lack of speci¢city and sensitivity of such testing, 2,3,9,17^19 and thereby the ability to satisfactorily di¡erentiate between benign and malignant disease. 1^3,9,18,21 While this contentious issue continues to be debated, 6, 9, 11 there are concerns as to whether tumour markers are already being used by clinicians as part of a diagnostic strategy for their patients, which may in turn partly explain why many hospital laboratories have been receiving increasing numbers of tumour marker requests despite a lack of an obvious change in cancer incidence or treatment during the same period.
This study was therefore undertaken with two main aims. The ¢rst was to identify the changes in tumour marker workload in a busy teaching hospital since 1997/98 and to identify the source of current requesting. The second aim was to take a sample of recent requests and to audit from case notes and reports whether tumour markers are being utilized in accordance with published clinical guidelines, or whether marker assays are also being performed in a screening capacity for suspected malignancies.
Methods

Patient population
All tumour marker requests sent to the Department of Clinical Biochemistry, Hull Royal In¢rmary, during the period 1 April 2001 to 31 March 2002 were included in the study. The markers routinely measured, together with their quoted reference intervals, are shown in Table 1 . Data collection of tumour marker results was performed by extracting them from the laboratory's pathology computer system (Masterlab, Torex Health Systems, She¤eld, UK) along with demographic details of age, sex, hospital number and the source of the request. To gauge the change in workload, the same data were gathered for the period 1 April 1997 to 31 March 1998.
From the 2001/02 data collection, a more detailed analysis was undertaken of individual cases identi¢ed from specimens sent on a single weekday (randomly chosen as 18 September 2001). These cases did not include any samples sent from general practitioners (GPs) in primary care because of the likely di¤culty in obtaining case records, so only requests from the Hull and East Yorkshire Hospitals NHS Trust were included. In addition, the decision was taken not to include patients with prostate-speci¢c antigen (PSA) requests in this part of the study because of the lack of consensus as to whether the test should be used in screening and/or case ¢nding for prostate cancer, with some authorities advocating its use 3,4,7,20 and others not. 2, 3 The detailed analysis took two forms. First, the case notes for each patient were examined and a questionnaire completed to establish details surrounding the timing and reasons for tumour marker requesting. Then, for each individual, the Masterlab laboratory computer system was used to identify (or con¢rm) the temporal relationship between tumour marker request(s) and biopsy diagnosis, or otherwise, of a malignancy.
Approval for the audit was gained from the Hull and East Yorkshire Hospitals NHS Trust prior to the data collection.
Laboratory assays
All tumour marker analyses were performed on a DPC Immulite 2000 immunoassay analyser (Diagnostics Products Corporation UK, Glyn Rhonwy, UK) with the exception of PSA testing which was conducted using an Abbott Architect i4000 immunoassay analyser (Abbott Diagnostics Division, Maidenhead, UK). All assays achieved satisfactory internal and external quality assessment during the study period.
Statistical analysis
Statistical analysis was performed using Microsoft Excel throughout.
Results
The Hull and East Yorkshire Hospitals NHS Trust carried out a total of 27 323 tumour marker tests on 13218 patients (9726 men, 3213 women, 279 sex unspeci¢ed; median age 67 years (interquartile range 57^76) between 1 April 2001 and 31 March 2002. Table 2 details the number of tumour marker requests (including and excluding PSA) from general practice and from secondary care outpatient clinics and ward areas. In relation to the change in tumour marker requesting since 1997/98, Fig. 1 shows the change in During the 12-month study period, 612 of the 3616 requests for CA125 were on male subjects, a further 98 out of 374 tests for CA15-3 were also on men, and 12 of the 11585 requests for PSA were on women. Sixty-six of the 98 men who had CA15-3 measured had biopsies examined in the year of the study or in the 2 years prior. None of these were on breast tissue.
From the patients tested on 18 September 2001, 34 ful¢lled the criteria of having been hospital inpatients or outpatients who were tested for one or more tumour markers other than PSA (median 2 markers, range 1^6). Figure 2 shows the number of cases in which tumour markers were tested either before or following a biopsy/cytology examination, as well as the number for which a biopsy was never performed. The results of the initial tumour marker requests for 19 of the study group members returned all results within stated reference intervals and 15 subjects showed one or more initial tumour marker results exceeding these ranges.
From the 19 cases in which tumour marker results returned within the reference intervals, Fig. 3 the completion of a biopsy study. The results of biopsies for 14 remaining subjects showed no indications of malignancy, whilst biopsies were not performed in four cases. From the 15 cases in which initial tumour marker testing indicated one or more result exceeding the stated reference intervals, Figure 3 also shows three did not include a biopsy study whilst 12 proceeded to undergo such a procedure. Of these 12 individuals, eight were diagnosed with malignant disease as a result of the biopsy report and four individuals showed no indications of malignancy.
Discussion
This study has provided an opportunity to assess the role that tumour markers are now ful¢lling in clinical practice, and to compare this role to that promoted by the published guidelines and recommendations. 2, 3, 8 It has also given a degree of insight into the place that tumour markers now have in the investigation and management of patients with cancer or suspected malignant disease. The data show that there has been a marked increase in the requesting of tumour markers in recent years, with a 125% rise overall between 1997/98 and 2001/02 (see Fig. 1 ). As cancer diagnoses have not risen by a similar proportion, it would be reassuring to suggest that this increase is either as a result of clinicians being more aware of the existence of tumour marker testing and/or because they are su¤ciently comfortable with the application and signi¢cance of these tests to use them more readily in appropriate patients.
Unfortunately, the ¢ndings of this study would suggest that this is not the only reason for the rise in requests. One other cause appears to be a degree of ignorance amongst healthcare sta¡ about which tumour marker is appropriate for which tumour type. For example, 17% of all CA125 requests (a marker typically associated with ovarian disease) and 26% of all CA15-3 tests (a common marker of breast malignancy) were performed on men. Despite the fact that these markers can be raised in other malignancies, it seems likely that many of these requests are inappropriate. Male breast cancer exists, but none of the men tested for CA15-3 had breast biopsies in the year of the study or the 2 years prior. Even for PSA, there was still a small (0.1%) number of cases where the test was also performed on the wrong sex of patient. This information would therefore suggest that there is not only a need to promote published guidelines but also a requirement to give more basic information regarding the use of these markers. The laboratory itself also has a responsibility in setting up systems that will highlight these requests before they are analysed.
As well as demonstrating a lack of knowledge, the use of tumour marker testing on the wrong sex of patient may also be indicative of the use of one or more of these tests to`screen' for cancer in someone not known to have malignant disease. The use of testing in this way in Hull (in discordance with the majority of guidelines relating to the issue) is corroborated by the fact that 1932 non-PSA results for tumour markers were issued from the accident and emergency and acute medical admission wards in the year studied. As one of the fundamental roles of these units is to acutely diagnose cases before forwarding them to other departments or wards, the necessity to perform tumour markers at this early stage is probably open to question.
The suspicion that tumour markers are being requested before a diagnosis is made was con¢rmed by the 34 cases studied at length. In the majority of instances a request for one or more tumour markers was issued before obtaining an appropriate diagnosis. As these tests were performed and their results returned to the clinicians before a conclusive tissue study was reported, it would seem proof that the ¢ndings of these tumour marker requests were being taken into account before a ¢nal diagnosis was reached.
Use of tumour markers in this manner would still be of value if they gave an accurate indication of whether the patient had malignancy or not, but, even in the small study sample, this was not the case. Instead, the data here con¢rm larger studies in showing that normal' tumour marker values can be falsely reassuring, while four of the 12 individuals with initial marker results exceeding the stated local reference intervals did not demonstrate any malignancy on biopsy. It is not possible to know from the current study whether the raised markers in these four individuals led to any undue distress or needless investigation on the part of the patient, as has been reported previously. 21 In summary, this study has demonstrated a substantial rise in serum tumour marker requests in a busy teaching hospital over a 4-year period. Some of this rise appears to be due to a lack of knowledge amongst some clinicians as to what malignancies a particular marker may be of value in. In other instances there is good evidence that, despite published guidelines, these tests are being used tò screen' for malignancy before a tissue diagnosis is made. In some of these cases, the results gained from the screen will have been falsely reassuring, while in others they are likely to have been unduly alarming. At the very least, these ¢ndings highlight the need for further educating clinical sta¡ in the use and misuse of tumour marker testing.
